Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Reuss

Showing results (71-80 of 136) with videos related to

Pageof 14
Sort By:
Clinical Sarcoma Research|February 28, 2019
Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotypeChristian Koelsche, Damian Stichel, Klaus G Griewank, et al.
Acta Neuropathologica|May 13, 2015
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHODavid E Reuss, Yasin Mamatjan, Daniel Schrimpf, et al.
Neuro-Oncology|May 5, 2022
HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant gliomaMarius Felix, Dennis Friedel, Ashok Kumar Jayavelu, et al.
Acta Neuropathologica|November 28, 2014
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastomaDavid E Reuss, Felix Sahm, Daniel Schrimpf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2023
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung CancerSamuel Rosner, Joshua E Reuss, Marianna Zahurak, et al.
Journal of Oncology Practice|August 7, 2019
Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and OutcomesAanika Balaji, Jiajia Zhang, Beatriz Wills, et al.
Frontiers in Oncology|May 11, 2023
<i>ERBB</i> family fusions are recurrent and actionable oncogenic targets across cancer typesLaura Schubert, Andrew Elliott, Anh T Le, et al.
Journal of Neuro-Oncology|July 21, 2022
Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysisAnna-Luisa Luger, Sven König, Patrick Felix Samp, et al.
Cancer Immunology, Immunotherapy : CII|February 26, 2022
Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitorsFyza Y Shaikh, Joell J Gills, Fuad Mohammad, et al.
Acta Neuropathologica|July 7, 2019
Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusionsDamian Stichel, Daniel Schrimpf, Belén Casalini, et al.
Pageof 14

Showing results (71-80 of 136) with videos related to

Sort By:
Pageof 14
Clinical Sarcoma Research|February 28, 2019
Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotypeChristian Koelsche, Damian Stichel, Klaus G Griewank, et al.
Acta Neuropathologica|May 13, 2015
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHODavid E Reuss, Yasin Mamatjan, Daniel Schrimpf, et al.
Neuro-Oncology|May 5, 2022
HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant gliomaMarius Felix, Dennis Friedel, Ashok Kumar Jayavelu, et al.
Acta Neuropathologica|November 28, 2014
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastomaDavid E Reuss, Felix Sahm, Daniel Schrimpf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2023
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung CancerSamuel Rosner, Joshua E Reuss, Marianna Zahurak, et al.
Journal of Oncology Practice|August 7, 2019
Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and OutcomesAanika Balaji, Jiajia Zhang, Beatriz Wills, et al.
Frontiers in Oncology|May 11, 2023
<i>ERBB</i> family fusions are recurrent and actionable oncogenic targets across cancer typesLaura Schubert, Andrew Elliott, Anh T Le, et al.
Journal of Neuro-Oncology|July 21, 2022
Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysisAnna-Luisa Luger, Sven König, Patrick Felix Samp, et al.
Cancer Immunology, Immunotherapy : CII|February 26, 2022
Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitorsFyza Y Shaikh, Joell J Gills, Fuad Mohammad, et al.
Acta Neuropathologica|July 7, 2019
Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusionsDamian Stichel, Daniel Schrimpf, Belén Casalini, et al.
Pageof 14